Drugs / Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04632992 | Jan 2021 → Dec 2023 | cancer of unknown primary site | Genentech, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2020-06-29 | Genentech, Inc. | Regulatory FDA Approves Genentech’s Phesgo (Fixed-Dose Combination of Perjeta and Herceptin for Subcutaneous Injection) for HER2-Positive Breast Cancer gene.com ↗
FDA Approves Genentech’s Phesgo (Fixed-Dose Combination of Perjeta and Herceptin for Subcutaneous Injection) for HER2-Positive Breast Cancer |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2020-06-29 | Genentech, Inc. | FDA Approves Genentech’s Phesgo (Fixed-Dose Combination of Perjeta and Herceptin for Subcutaneous Injection) for HER2-Positive Breast Cancer gene.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04632992 ↗ |
| Route | Subcutaneous | “PH FDC SC will be administered subcutaneously (SC) at a fixed non-weight-based dose.” NCT04632992 ↗ |